AI assistant
Aurobindo Pharma Ltd. Interim / Quarterly Report 2026
61251_rns_2026-05-21_f6de87c6-156d-4cea-97a6-ad38dda0419d.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
AUROBINDO
May 21, 2026
| To
Listing Department,
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex, Bandra (E),
MUMBAI -400 051
Company Code No. AUROPHARMA | To
The Corporate Relations Department
BSE LIMITED
Phiroz Jeejeebhoy Towers, 25^{th} floor, Dalal Street,
MUMBAI -400 001
Company Code No. 524804 |
| --- | --- |
Dear Sir / Madam,
Sub: Outcome of the Board Meeting held on May 21, 2026.
The Board of Directors of the Company at its meeting held today, May 21, 2026, has, inter alia, considered and approved: -
(a) the standalone and consolidated Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Audited Financial Results of the Company along with the Auditors Reports issued by the Statutory Auditors.
Pursuant to Regulation 33(3)(d) of the SEBI Listing Regulations, we hereby confirm and declare that the Statutory Auditors of the Company, M/s. Deloitte Haskins & Sells, Chartered Accountants, have issued the audit reports on Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2026, with unmodified opinion.
(b) the resignation of M/s. MRR & Associates as Secretarial Auditor of the Company effective from May 22, 2026, due to health issues of its sole proprietor.
The details required in terms of Regulation 30 of the SEBI Listing Regulations are provided in Annexure-1.
(c) the appointment of M/s. RPR & Associates, Company Secretaries in Practice as the Secretarial Auditors of the Company for a term of five consecutive years commencing from FY 2026-27, subject to approval of the shareholders of the Company at the ensuing Annual General Meeting.
The details required in terms of Regulation 30 of the SEBI Listing Regulations are provided in Annexure-2.
(d) the re-appointment of M/s. Ernst & Young LLP as Internal Auditors of the Company for the period from June 2026 to May 2027.
AUROBINDO PHARMA LIMITED
(CIN: L24239TG1986PLC015190)
www.aurobin do.com
Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.
Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobin do.com Website: www.aurobin do.com
AUROBINDO
The details required in terms of Regulation 30 of the SEBI Listing Regulations are provided in Annexure-3.
The Board meeting commenced at 4:30 p.m. and concluded at 6:25 p.m.
Please take the information on record.
Yours faithfully,
For AUROBINDO PHARMA LIMITED
Digitally signed by ADI REDDY
BADDIGAM
Date: 2026.05.21 19:26:16 +05'30'
B. Adi Reddy
Company Secretary
Encl: as above.
(CIN: L24239TG1986PLC015190)
A U R O B I N D O P H A R M A L I M I T E D
www.aurobindo.com
Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.
Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: [email protected] Website: www.aurobindo.com
AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)
www.aurobindo.com
Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India
Tel: +91 (40) 66721200; Fax: +91 40 23741080; Email: [email protected]
(All amounts are in ₹ million, unless otherwise stated)
| STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2026 AND UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2026 | ||||||
|---|---|---|---|---|---|---|
| Particulars | Quarter ended | Year ended | ||||
| 31.03.2026 | 31.12.2025 | 31.03.2025 | 31.03.2026 | 31.03.2025 | ||
| Unaudited (Refer note 7) | Unaudited | Unaudited (Refer note 7) | Audited | Audited | ||
| 1 | Revenue from operations | |||||
| (a) Net sales/ income from operations | 27,469.8 | 27,263.8 | 27,214.3 | 1,10,553.9 | 1,07,880.9 | |
| (b) Other operating income | 395.7 | 209.0 | 105.6 | 1,163.3 | 1,452.1 | |
| 2 | Total revenue from operations | 27,865.5 | 27,472.8 | 27,319.9 | 1,11,717.2 | 1,09,333.0 |
| Other income | ||||||
| (a) Foreign exchange gain (net) | 203.5 | 589.7 | 501.4 | 1,790.7 | 1,181.1 | |
| 3 | (b) Others | 1,937.4 | 711.8 | 638.4 | 4,084.6 | 2,100.1 |
| Total other income | 2,140.9 | 1,301.5 | 1,139.8 | 5,875.3 | 3,281.2 | |
| Total income (1+2) | 30,006.4 | 28,774.3 | 28,459.7 | 1,17,592.5 | 1,12,614.2 | |
| 4 | Expenses | |||||
| (a) Cost of materials consumed | 12,516.6 | 14,025.5 | 13,607.0 | 52,383.8 | 56,102.1 | |
| (b) Purchase of stock-in-trade | 165.2 | 201.5 | 163.1 | 732.0 | 651.3 | |
| (c) Changes in inventories of finished goods, stock-in-trade and work-in-progress | 427.9 | (1,359.9) | 605.2 | 465.5 | (676.6) | |
| (d) Employee benefits expense | 2,927.1 | 2,911.0 | 2,731.1 | 11,611.5 | 10,630.7 | |
| (e) Finance costs | 472.7 | 484.3 | 610.9 | 2,131.5 | 2,300.4 | |
| (f) Depreciation and amortisation expenses | 719.3 | 719.2 | 938.8 | 2,853.6 | 2,972.0 | |
| (g) Other expenses | 4,014.5 | 3,799.9 | 4,248.4 | 15,605.0 | 17,049.8 | |
| Total expenses | 21,243.3 | 20,781.5 | 22,904.5 | 85,782.9 | 89,029.7 | |
| 5 | Profit before exceptional items and tax (3-4) | 8,763.1 | 7,992.8 | 5,555.2 | 31,809.6 | 23,584.5 |
| 6 | Exceptional items (refer note 4) | - | 173.8 | - | 173.8 | - |
| 7 | Profit before tax (5-6) | 8,763.1 | 7,819.0 | 5,555.2 | 31,635.8 | 23,584.5 |
| 8 | Tax expense | |||||
| Current tax | 1,819.5 | 2,029.7 | 1,552.5 | 7,468.2 | 6,273.7 | |
| Deferred tax | 21.3 | (31.4) | (79.0) | 19.6 | (157.1) | |
| Total tax expense | 1,840.8 | 1,998.3 | 1,473.5 | 7,487.8 | 6,116.6 | |
| 9 | Profit after tax (7-8) | 6,922.3 | 5,820.7 | 4,081.7 | 24,148.0 | 17,467.9 |
| 10 | Other comprehensive income | |||||
| Items that will not be reclassified subsequently to profit or loss: | ||||||
| (a) Re-measurement of defined benefit liability | 48.4 | (15.9) | (12.1) | 14.5 | (70.3) | |
| (b) Income-tax relating to items that will not be reclassified to profit or loss | (12.2) | 4.0 | 3.0 | (3.7) | 17.7 | |
| Total other comprehensive income/(loss) (net of tax) | 36.2 | (11.9) | (9.1) | 10.8 | (52.6) | |
| Total comprehensive income (9+10) | 6,958.5 | 5,808.8 | 4,072.6 | 24,158.8 | 17,415.3 | |
| Paid-up equity share capital (face value ₹ 1 per share) | 580.8 | 580.8 | 580.8 | 580.8 | 580.8 | |
| 13 | Other equity | 2,26,596.1 | 2,04,760.3 | |||
| Earnings per equity share (face value ₹ 1 per share) | (Not annualised) | (Not annualised) | (Not annualised) | (Annualised) | (Annualised) | |
| (a) Basic (in ₹) | 11.92 | 10.02 | 7.03 | 41.58 | 29.97 | |
| (b) Diluted (in ₹) | 11.92 | 10.02 | 7.03 | 41.58 | 29.97 |
Standalone Balance Sheet
(All amounts are in ¥ million, unless otherwise stated)
| Sl. No. | Particulars | As at 31.03.2026 | As at 31.03.2025 |
|---|---|---|---|
| Audited | Audited | ||
| 1 | ASSETS | ||
| Non-current assets | |||
| Property, plant and equipment | 23,177.6 | 21,664.9 | |
| Capital work-in-progress | 2,285.5 | 875.3 | |
| Right-of-use assets | 1,021.7 | 188.0 | |
| Goodwill | 917.0 | 917.0 | |
| Other intangible assets | 321.0 | 598.1 | |
| Financial assets | |||
| Investments | 1,68,361.5 | 1,52,095.6 | |
| Loans | 12,104.5 | 16,543.2 | |
| Trade receivables | - | - | |
| Other financial assets | 490.4 | 431.6 | |
| Income tax assets (net) | 2,902.1 | 2,791.5 | |
| Other non-current assets | 993.7 | 2,131.4 | |
| Total non-current assets | 2,12,575.0 | 1,98,236.6 | |
| 2 | Current assets | ||
| Inventories | 23,605.7 | 23,592.8 | |
| Financial assets | |||
| Investments | 7,262.0 | 0.1 | |
| Trade receivables | 42,096.8 | 41,950.5 | |
| Cash and cash equivalents | 1,604.3 | 2,952.6 | |
| Bank balances other than cash and cash equivalents | 20.7 | 31.0 | |
| Loans | 56.9 | 54.4 | |
| Other financial assets | 32.3 | 2,062.7 | |
| Other current assets | 5,540.1 | 6,249.9 | |
| Total current assets | 80,218.8 | 76,894.0 | |
| TOTAL ASSETS (1+2) | 2,92,793.8 | 2,75,130.6 | |
| 1 | EQUITY AND LIABILITIES | ||
| Equity | |||
| Equity share capital | 580.8 | 580.8 | |
| Other equity | 2,26,596.1 | 2,04,760.3 | |
| Total equity | 2,27,176.9 | 2,05,341.1 | |
| 2 | Liabilities | ||
| Non-current liabilities | |||
| Financial liabilities | |||
| Borrowings | - | 4,000.0 | |
| Lease liabilities | 854.1 | 37.2 | |
| Provisions | 731.7 | 533.0 | |
| Deferred tax liability (net) | 1,037.6 | 1,014.3 | |
| Total non-current liabilities | 2,623.4 | 5,584.5 | |
| 3 | Current liabilities | ||
| Financial liabilities | |||
| Borrowings | 41,824.7 | 42,250.9 | |
| Lease liabilities | 173.6 | 177.9 | |
| Trade payables | |||
| total outstanding dues of micro enterprises and small enterprises | 782.0 | 378.4 | |
| total outstanding dues of creditors other than micro enterprises and small enterprises | 17,538.0 | 17,495.8 | |
| Other financial liabilities | 1,479.7 | 2,761.5 | |
| Other current liabilities | 412.4 | 290.4 | |
| Provisions | 245.8 | 213.5 | |
| Current tax liabilities (net) | 537.3 | 636.6 | |
| Total current liabilities | 62,993.5 | 64,205.0 | |
| TOTAL EQUITY AND LIABILITIES (1+2+3) | 2,92,793.8 | 2,75,130.6 |
Standalone Statement of Cash Flows
(All amounts are in ¥ million, unless otherwise stated)
| Sl. No. | Particulars | For the year ended 31.03.2026 | For the year ended 31.03.2025 |
|---|---|---|---|
| Audited | Audited | ||
| 1 | CASH FLOW FROM OPERATING ACTIVITIES | ||
| Net profit before tax | 31,635.8 | 23,584.5 | |
| Adjustments for: | |||
| Depreciation and amortisation expenses | 2,853.6 | 2,972.0 | |
| Allowance for expected credit losses (net) | (164.5) | 49.8 | |
| Provision for diminution of investment | - | 137.6 | |
| Provisions no longer required written back | - | (25.4) | |
| Unrealised foreign exchange gain (net) | (689.0) | (853.0) | |
| Profit on sale of property, plant and equipment (net) | (5.6) | (21.0) | |
| Dividend income | (2,300.8) | - | |
| Profit on sale of investments | (14.1) | (53.8) | |
| Finance costs | 2,117.3 | 2,286.5 | |
| Interest income | (1,060.4) | (1,651.5) | |
| Operating profit before working capital changes | 32,372.3 | 26,425.7 | |
| Movements in working capital: | |||
| (Increase)/decrease in trade receivables | 2,230.0 | (3,500.9) | |
| (Increase)/decrease in inventories | (12.8) | 83.2 | |
| (Increase)/decrease in loans | (4.9) | (11.7) | |
| (Increase)/decrease in other financial assets | 1,329.5 | 114.8 | |
| (Increase)/decrease in other assets | 1,939.0 | 1,610.5 | |
| Increase/(decrease) in trade payables | 99.5 | (42.9) | |
| Increase/(decrease) in provision for employee benefits | 245.4 | 35.9 | |
| Increase/(decrease) in other financial liabilities | (1,311.7) | (1,060.2) | |
| Increase/(decrease) in other liabilities | 122.0 | (504.9) | |
| Cash generated from operating activities | 37,008.3 | 23,149.5 | |
| Income-tax paid (net) | (7,678.1) | (6,691.6) | |
| Net cash flow generated from operating activities (A) | 29,330.2 | 16,457.9 | |
| 2 | CASH FLOW FROM INVESTING ACTIVITIES | ||
| Purchase of property, plant and equipment including movement in capital work-in-progress, capital advances and capital creditors | (5,206.1) | (2,469.4) | |
| Proceeds from sale of property, plant and equipment | 621.2 | 554.5 | |
| Purchase of non-current investments | (11,420.0) | (16,125.1) | |
| Proceeds from redemption of debentures | 7,614.9 | 11,000.0 | |
| Proceeds from sale of non-current investments | 5,800.0 | - | |
| Purchase of current investments (net) | (7,247.8) | - | |
| Profit from sale of current investments | - | 53.8 | |
| Dividend received from subsidiaries | 2,300.8 | - | |
| Loans given to subsidiaries | (23,970.0) | (18,110.0) | |
| Loans repaid by subsidiaries | 8,801.0 | 3,585.8 | |
| Interest received | 2,446.1 | 772.3 | |
| Movement in other bank balances (net) | 10.3 | 79.1 | |
| Net cash flow used in investing activities (B) | (20,249.6) | (20,659.0) | |
| 3 | CASH FLOW FROM FINANCING ACTIVITIES | ||
| Buy back of equity shares (including tax and transaction cost) | - | (9,302.4) | |
| Proceeds from non current borrowings | 1,800.0 | 12,000.0 | |
| Repayment of non current borrowings | (7,700.0) | (300.0) | |
| Proceeds/(repayment) of current borrowings (net) | (116.6) | 6,232.9 | |
| Repayment of lease liabilities | (240.5) | (239.3) | |
| Interest paid | (2,142.4) | (2,222.7) | |
| Dividend paid | (2,324.0) | (5.4) | |
| Net cash generated from/(used in) financing activities (C) | (10,723.5) | 6,163.1 | |
| Net Increase/(decrease) in cash and cash equivalents (A+B+C) | (1,642.9) | 1,962.0 | |
| Cash and cash equivalents at the beginning of the year | 2,952.6 | 833.2 | |
| Effect of exchange differences on cash and cash equivalents | 294.6 | 157.4 | |
| Cash and cash equivalents at the end of the year | 1,604.3 | 2,952.6 | |
| Cash and cash equivalents comprises of: | |||
| Cash on hand | - | 0.6 | |
| Balance with banks | 1,604.3 | 2,952.0 | |
| Cash and cash equivalents considered for cash flows | 1,604.3 | 2,952.6 |
NOTES:
-
The above standalone financial results of Aurobindo Pharma Limited ("the Company") has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
-
The above standalone financial results of the Company as reviewed by the Audit Committee have been approved by the Board of Directors at its meeting held on May 21, 2026. The results for the year ended March 31, 2026 has been audited and for the quarter ended March 31, 2026 has been reviewed by our statutory auditors. The statutory auditors of the Company have expressed an unmodified opinion on the financial results for the year ended March 31, 2026 and have issued an unmodified conclusion in respect of the limited review for the quarter ended March 31, 2026.
-
The Company operates in only one reportable segment viz., 'Pharmaceuticals' in accordance with Ind AS 108, "Operating Segment".
-
On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Labour Codes, amongst other things introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability (arising out of past service cost) and increase in leave liability aggregating ₹ 173.8 million. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Company has presented this incremental amount under "Exceptional Items" in the Standalone Statement of Profit and Loss for the quarter ended December 31, 2025 and year ended March 31, 2026. The Company continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of liability pertaining to employee benefits.
-
The Board of Directors at their meeting held on April 06, 2026, approved buyback of 5,423,728 fully paid-up equity shares of face value of ₹ 1 each (representing 0.93% of the total number of equity shares of the Company) for an aggregate value not exceeding ₹ 8,000.0 million (Buyback Size) (excluding transaction cost) at a maximum buy back price of ₹ 1,475/- per equity share.
The buyback offer is made to all of the equity shareholders of the Company, including the promoters and members of the promoter group of the Company (as defined under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011), who hold Equity Shares as of the record date (April 17, 2026), on proportionate basis through the tender offer route in accordance with the Companies Act, 2013, as amended, rules made thereunder, the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended ("Buyback Regulations") and other applicable laws.
Pursuant to the buyback offer, 5,423,728 equity shares were accepted and consideration of ₹ 8,000.0 million was paid to eligible shareholders on May 07, 2026.
-
The Board of Directors of the Company at its meeting held on April 06, 2026 approved the transfer of domestic branded generic pharmaceutical formulations products business on a going concern basis through a Business Transfer Agreement ("BTA") to Auropharm Limited (previously known as Auro Pharma Limited), a wholly owned subsidiary of the Company on a going concern basis by way of a slump sale w.e.f April 01, 2026 subject to certain conditions precedent including receipt of requisite approvals.
-
The figures for the current quarter and quarter ended March 31, 2025, are the balancing figures between the audited figures in respect of full financial year ended March 31, 2026 and March 31, 2025, respectively and published year to date figures up to third quarter ended December 31, 2025 and December 31, 2024, respectively, which were subject to limited review by the statutory auditors.
By Order of the Board
For Aurobindo Pharma Limited
K. Nithyananda Ridgley
Vice Chairman & Managing Director
DIN-01284195
Place: Hyderabad
Date: May 21, 2026
Page 4 of 4
Deloitte Haskins & Sells
Chartered Accountants
Meenakshi Pride Rock Tower III
[Block - M], 8th & 9th floors
Survey No. 23, Gachibowli
Serilingampally Municipality
Ranga Reddy District
Hyderabad-500032
Telangana, India
INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS
TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED
Opinion and Conclusion
We have (a) audited the Standalone Financial Results for the year ended March 31, 2026 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2026 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of audited standalone financial results for the year ended March 31, 2026 and unaudited standalone financial results for the quarter ended March 31, 2026" of AUROBINDO PHARMA LIMITED (the "Company"), (the "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").
(a) Opinion on Annual Standalone Financial Results
In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2026:
i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the year then ended.
(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2026
With respect to the Standalone Financial Results for the quarter ended March 31, 2026, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2026, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2026
We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.
Management's and Board of Directors' Responsibilities for the Statement
This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2026 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2026 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other
Deloitte Haskins & Sells
irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.
In preparing the Standalone Financial Results, the Board of Directors is responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
The Board of Directors is also responsible for overseeing the financial reporting process of the Company.
Auditor's Responsibilities
(a) Audit of the Standalone Financial Results for the year ended March 31, 2026
Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.
As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
-
Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
-
Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
-
Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
-
Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
-
Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
-
Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
-
Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.
L
Deloitte Haskins & Sells
Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.
We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.
We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
(b) Review of the Standalone Financial Results for the quarter ended March 31, 2026
We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2026 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under Section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
Other Matters
The Statement includes the results for the Quarter ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.
Our report on the Statement is not modified in respect of this matter.
For DELOITTE HASKINS & SELLS
Chartered Accountants
(Firm's Registration No. 008072S)
C Manish Muralidhar
Partner
(Membership No. 213649)
(UDIN: 26213649BXBGMY5881)
Place: Nellore
Date: May 21, 2026
AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)
www.aurobinfo.com
Regd. Office: Plot No.2, Maitrivihar, Amerpret, Hyderabad - 500 038, India
Tel: +91 (40) 66721200; Fax: +91 40 23741080; Email: [email protected]
(All amounts are in ₹ million, unless otherwise stated)
| STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR YEAR ENDED MARCH 31, 2026 AND UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2026 |
|---|
| 31.03.2026 |
| Unaudited (Refer note 10) |
| 1 |
| (a) Net sales/ income from operations |
| (b) Other operating income |
| 2 |
| Other income |
| (a) Foreign exchange gain (net) |
| 3 |
| Total other income |
| Total income (1+2) |
| 4 |
| (a) Cost of materials consumed |
| (b) Purchase of stock-in-trade |
| (c) Changes in inventories of finished goods, stock-in-trade and work-in-progress |
| (d) Employee benefits expense |
| (e) Finance costs |
| (f) Foreign exchange loss (net) |
| (g) Depreciation, amortisation and impairment expense |
| (h) Other expenses |
| Total expenses |
| 4 |
| 5 |
| 6 |
| Exceptional items (refer note 8) |
| 8 |
| Tax expense |
| 9 |
| Deferred tax |
| Total tax expense |
| 10 |
| 11 |
| A) Items that will not be reclassified subsequently to profit or loss: |
| i) Re-measurement of defined employee benefit liability |
| ii) Equity investments through other comprehensive income - net change in fair value |
| iii) Income-tax relating to items that will not be reclassified to profit or loss |
| B) Items that will be reclassified subsequently to profit or loss: |
| i) Exchange differences on translating the financial statements of foreign operations |
| ii) Income-tax on items that will be reclassified subsequently to profit or loss |
| Total other comprehensive income (net of tax) |
| 12 |
| 13 |
| Owners of the Parent Company |
| Non-controlling interest |
| Out of total comprehensive income above, |
| Profit after tax attributable to: |
| Owners of the Parent Company |
| Non-controlling interest |
| Other comprehensive income/(loss) attributable to: |
| Owners of the Parent Company |
| Non-controlling interest |
| Paid-up equity share capital (face value ₹ 1 per share) |
| 14 |
| Earnings per equity share (face value ₹ 1 per share) |
| (a) Basic (in ₹) |
| (b) Diluted (in ₹) |
LILAN HASKINS & SHORTENBERG ACCOUNTANTS
A
A
Consolidated Balance Sheet
(All amounts are in % million, unless otherwise stated)
| Sl. No. | Particulars | As at 31.03.2026 | As at 31.03.2025 |
|---|---|---|---|
| Audited | Audited | ||
| 1 | ASSETS | ||
| Non-current assets | |||
| Property, plant and equipment | 1,39,552.0 | 1,18,950.2 | |
| Capital work-in-progress | 30,088.3 | 32,660.0 | |
| Right-of-use assets | 3,747.3 | 2,944.1 | |
| Goodwill | 8,001.5 | 6,180.2 | |
| Other intangible assets | 22,765.0 | 19,867.4 | |
| Intangible assets under development | 22,047.3 | 16,339.6 | |
| Investments accounted for using the equity method | 1,088.4 | 455.4 | |
| Financial assets | |||
| Investments | 1,950.4 | 2,061.6 | |
| Loans | 75.7 | 67.4 | |
| Trade receivables | - | 1,083.2 | |
| Other financial assets | 5,499.0 | 5,377.1 | |
| Deferred tax assets (net) | 14,835.9 | 12,929.6 | |
| Non-current tax assets (net) | 4,524.3 | 4,370.8 | |
| Other non-current assets | 3,758.9 | 2,938.5 | |
| Total non-current assets | 2,57,934.0 | 2,26,225.1 | |
| 2 | Current assets | ||
| Inventories | 1,20,529.4 | 1,05,437.2 | |
| Financial assets | |||
| Investments | 7,472.4 | 0.1 | |
| Trade receivables | 70,943.7 | 57,459.3 | |
| Cash and cash equivalents | 71,914.0 | 55,689.5 | |
| Bank balances other than cash and cash equivalents | 26,788.9 | 26,665.4 | |
| Loans | 178.7 | 155.6 | |
| Other financial assets | 1,009.5 | 2,619.5 | |
| Current tax assets (net) | 216.8 | 27.8 | |
| Other current assets | 28,034.1 | 23,570.2 | |
| Total current assets | 3,27,087.5 | 2,71,624.6 | |
| TOTAL ASSETS (1+2) | 5,85,021.5 | 4,97,849.7 | |
| 1 | EQUITY AND LIABILITIES | ||
| 2 | Equity | ||
| Equity share capital | 580.8 | 580.8 | |
| Other equity | 3,78,328.9 | 3,25,952.4 | |
| Equity attributable to owners of the Parent Company | 3,78,909.7 | 3,26,533.2 | |
| Non-controlling interest | (81.6) | (63.9) | |
| Total equity | 3,78,828.1 | 3,26,469.3 | |
| Liabilities | |||
| Non-current liabilities | |||
| Financial liabilities | |||
| Borrowings | 8,027.5 | 15,616.5 | |
| Lease liabilities | 2,929.4 | 2,392.1 | |
| Others | 2,418.7 | 141.0 | |
| 3 | Provisions | 4,004.1 | 2,829.3 |
| Deferred tax liabilities (net) | 3,060.0 | 3,032.7 | |
| Other non-current liabilities | 5,363.6 | 545.4 | |
| 3 | Total non-current liabilities | 25,803.3 | 24,557.0 |
| Current liabilities | |||
| Financial liabilities | |||
| Borrowings | 68,734.5 | 63,800.3 | |
| Lease liabilities | 1,037.0 | 819.8 | |
| Trade payables | |||
| total outstanding dues of micro enterprises and small enterprises | 1,918.8 | 862.3 | |
| total outstanding dues of creditors other than micro enterprises and small enterprises | 53,753.9 | 41,026.2 | |
| Other financial liabilities | 43,046.5 | 29,241.6 | |
| Other current liabilities | 6,263.0 | 5,468.3 | |
| Provisions | 3,530.4 | 2,755.6 | |
| Current tax liabilities (net) | 2,106.0 | 2,849.3 | |
| Total current liabilities | 1,80,390.1 | 1,46,823.4 | |
| TOTAL EQUITY AND LIABILITIES (1+2+3) | 5,85,021.5 | 4,97,849.7 |
Consolidated Statement of Cash Flows
(All amounts are in % million, unless otherwise stated)
| Sl. No. | Particulars | For the year ended 31.03.2026 | For the year ended 31.03.2025 |
|---|---|---|---|
| Audited | Audited | ||
| 1 | CASH FLOW FROM OPERATING ACTIVITIES | ||
| Net profit before tax | 51,118.5 | 50,662.9 | |
| Adjustments for: | |||
| Depreciation, amortisation and impairment expense | 17,781.9 | 16,494.2 | |
| Allowance for expected credit losses (net) | 132.6 | 188.0 | |
| Liabilities no longer required written back | (38.9) | (121.4) | |
| Unrealised exchange loss (net) | 2,209.8 | 755.9 | |
| Loss on sale of property, plant and equipment (net) | 243.0 | 89.4 | |
| Write-off of intangible assets under development (net) | 317.6 | 114.2 | |
| Share of loss of associates and joint ventures | (15.2) | 316.9 | |
| Profit on sale of investments | (14.2) | (367.0) | |
| Dividend income | (22.7) | - | |
| Finance costs | 3,523.1 | 4,403.8 | |
| Interest income | (3,290.8) | (3,532.4) | |
| Operating profit before working capital changes | 71,944.7 | 69,004.5 | |
| Movements in working capital: | |||
| (Increase)/decrease in inventories | (14,997.6) | (7,354.9) | |
| (Increase)/decrease in trade receivables | (11,707.3) | (8,620.8) | |
| (Increase)/decrease in other financial assets | 1,556.0 | (1,716.1) | |
| (Increase)/decrease in other assets | (4,202.8) | 1,712.7 | |
| Increase/(decrease) in trade payables | 12,815.7 | (3,108.9) | |
| Increase/(decrease) in provision | 1,996.4 | 589.9 | |
| Increase/(decrease) in other financial liabilities | 10,571.5 | 9,368.3 | |
| Increase/(decrease) in other liabilities | 5,607.4 | (3,315.0) | |
| Cash generated from operating activities | 73,584.0 | 56,559.7 | |
| Income taxes paid (net of refunds) | (18,320.3) | (17,313.5) | |
| Net cash generated from operating activities (A) | 55,263.7 | 39,246.2 | |
| 2 | CASH FLOW FROM INVESTING ACTIVITIES | ||
| Purchase of property, plant and equipment, including movement in capital work- in- progress, capital advances and capital creditors (net) | (26,857.7) | (19,678.6) | |
| Purchase of intangible assets and intangible assets under development | (4,189.0) | (5,516.9) | |
| Proceeds from sale of property, plant and equipment | 462.5 | 28.4 | |
| Purchase of controlling interest in subsidiaries | (31.7) | (113.9) | |
| Purchase of non-current investments | (650.6) | (230.2) | |
| Proceeds from sale of non-current investments | 58.7 | 22.5 | |
| Acquisition of business (refer note 7) | (3,000.0) | - | |
| (Purchase)/proceeds from sale of current investments (net) | (7,227.0) | 1,089.3 | |
| Movement in other bank balances | 3,540.4 | 2,167.7 | |
| Dividend received | 22.7 | - | |
| Interest received | 3,285.6 | 3,473.7 | |
| Net cash used in investing activities (B) | (34,586.1) | (18,758.0) | |
| 3 | CASH FLOW FROM FINANCING ACTIVITIES | ||
| Buy back of equity shares (including tax and transaction cost) | - | (9,302.4) | |
| Proceeds from non-current borrowings | 3,606.8 | 6,614.3 | |
| Repayment of non-current borrowings | (13,039.8) | (11,188.6) | |
| Proceeds of current borrowings (net) | 3,591.8 | 20,611.4 | |
| Interest paid | (3,440.9) | (4,203.2) | |
| Repayment of lease liabilities | (1,085.4) | (1,098.3) | |
| Acquisition of non-controlling interest in subsidiary | - | (225.0) | |
| Dividend paid | (2,324.0) | (10.4) | |
| Net cash (used in) / generated from financing activities (C) | (12,691.5) | 1,197.8 | |
| Net increase in cash and cash equivalents (A+B+C) | 7,986.1 | 21,686.0 | |
| Cash and cash equivalents at the beginning of the year | 55,637.9 | 33,854.3 | |
| Add: Cash and cash equivalents on acquisition of a subsidiary | 1.8 | 6.6 | |
| Effect of exchange differences on cash and cash equivalents | 8,288.2 | 91.0 | |
| Cash and cash equivalents at the end of the year | 71,914.0 | 55,637.9 | |
| Cash and cash equivalents comprise of: | |||
| Cash on hand | 2.0 | 2.1 | |
| Balance with banks | |||
| - in current account | 18,145.2 | 26,491.7 | |
| - in money market | 1,260.2 | 1,046.6 | |
| - in deposit account | 52,506.6 | 28,149.1 | |
| Cash and cash equivalents | 71,914.0 | 55,689.5 | |
| Overdraft used for cash and cash management | - | 51.6 | |
| Cash and cash equivalents considered for cash flows | 71,914.0 | 55,637.9 |
CITY OF HASKINGTON
Page 3 of 4
NOTES:
-
The above consolidated financial results of Aurobindo Pharma Limited ("the Company") including its subsidiaries (collectively known as "the Group") and its associates and joint ventures have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
-
The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "investments in Associates and Joint ventures" notified under Section 133 of the Act and Companies (Indian Accounting Standards) Rules, 2015, as amended.
-
The above consolidated financial results of the Group as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on May 21, 2026. The results for the year ended March 31, 2026 has been audited and for the quarter ended March 31, 2026 has been reviewed by our statutory auditors. The statutory auditors of the Company have expressed an unmodified opinion on the financial results for the year ended March 31, 2026 and have issued an unmodified conclusion in respect of the limited review for the quarter ended March 31, 2026.
-
The Group operates in only one reportable segment viz., 'Pharmaceuticals' in accordance with Ind AS 108, "Operating Segment".
-
During the year ended March 31, 2026:
(i) The Company, incorporated a step-down subsidiary, CuraTeQ Biologics B.V., Netherlands through CuraTeQ Biologics Private Limited, India (wholly owned subsidiary) on May 28, 2025.
(ii) The Company, incorporated a step-down subsidiary, Cresedemo Pharma LLC through Aurobindo Pharma USA Inc., (wholly owned subsidiary) on June 13, 2025.
(iii) The Company, incorporated a step-down subsidiary, Aurobindo Pharma (Malaysia) SDN. BHD. through Helix Healthcare B.V., The Netherlands, (wholly owned subsidiary) on September 17, 2025.
(iv) The Company, incorporated a step-down subsidiary, CuraTeQ Biologics (Malta) Limited through CuraTeQ Biologics B.V., The Netherlands, (wholly owned subsidiary) on September 26, 2025.
(v) Pharmacin B.V (wholly owned subsidiary of Agile Pharma BV) merged with Agile Pharma BV (wholly owned subsidiary of Helix Healthcare B.V., The Netherlands) w.e.f. July 1, 2025.
(vi) Helix Healthcare B.V, The Netherlands, (wholly owned subsidiary) has transferred its 100% stake in CuraTeQ Biologics s.r.o., Czech Republic (wholly owned subsidiary) to CuraTeQ Biologics B.V, The Netherlands (wholly owned subsidiary) w.e.f. July 29, 2025.
(vii) The Company, incorporated a step-down subsidiary, Aurobindo Pharma Chile SpA through Helix Healthcare B.V, (wholly owned subsidiary) on October 07, 2025.
(viii) The Company, incorporated a step-down subsidiary, Eugia Pharma Chile SpA through Eugia Pharma B.V, (wholly owned subsidiary) on October 07, 2025.
(ix) The Company, incorporated a step-down subsidiary, Aurobindo Pharma Philippines Inc. through Helix Healthcare B.V, (wholly owned subsidiary) on January 23, 2026.
(x) The Company, incorporated a wholly owned subsidiary, Engenra Biologics Private Limited on February 24, 2026.
(xi) The Company, acquired Diadame Pharma SARL, Senegal through its wholly owned step-down subsidiary Arrow Generiques SAS on January 01, 2026.
-
During the year, Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company, has entered into a definitive agreement to acquire 100% of membership interest in Lannett Company LLC. The proposed transaction is subject to certain regulatory approvals. Accordingly, no financial impact has arisen in the quarter and year ended March 31, 2026.
-
On January 01, 2026, Auropharm Limited (a wholly owned subsidiary of the Company), signed a Business transfer agreement to purchase non-oncology prescription formulations business from M/s Khandelwal Laboratories Private Limited on a going concern basis. The acquisition includes transfer of Brands, workforce etc., for a total consideration of ₹ 3,250 million, consisting of an upfront cash payment of ₹ 3,000 million, and a deferred consideration upto ₹ 250 million which is payable subject to certain conditions precedence.
-
On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, ('Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefits during employment and post-employment. The Labour Codes, amongst other things introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability (arising out of past service cost) and increase in leave liability aggregating ₹ 653.3 million. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Group has presented this incremental amount under "Exceptional Items" in the Consolidated Statement of Profit and Loss for the quarter ended December 31, 2025 and year ended March 31, 2026. The Group continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of liability pertaining to employee benefits.
-
The Board of Directors at their meeting held on April 06, 2026, approved buyback of 5,423,728 fully paid-up equity shares of face value of ₹ 1 each (representing 0.93% of the total number of equity shares of the Company) for an aggregate value not exceeding ₹ 8,000.0 million (Buyback Size) (excluding transaction cost) at a maximum buy back price of ₹ 1,475/- per equity share.
The buyback offer is made to all of the equity shareholders of the Company, including the promoters and members of the promoter group of the Company (as defined under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011), who hold Equity Shares as of the record date (April 17, 2026), on proportionate basis through the tender offer route in accordance with the Companies Act, 2013, as amended, rules made thereunder, the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended ("Buyback Regulations") and other applicable laws.
Pursuant to the buyback offer, 5,423,728 equity shares were accepted and consideration of ₹ 8,000.0 million was paid to eligible shareholders on May 07, 2026.
- The figures for the current quarter and quarter ended March 31, 2025, are the balancing figures between the audited figures in respect of full financial year ended March 31, 2026 and March 31, 2025, respectively and published year to date figures up to third quarter ended December 31, 2025 and December 31, 2024, respectively, which were subject to limited review by the statutory auditors.
By Order of the Board
For Aurobindo Pharma Limited
K.Nithyalianda Reddy
Vice Chairman & Managing Director
DIN-01284195
Page 4 of 4
Deloitte Haskins & Sells
Chartered Accountants
Meenakshi Pride Rock Tower III
[Block - M], 8th & 9th floors
Survey No. 23, Gachibowli
Serilingampally Municipality
Ranga Reddy District
Hyderabad-500032
Telangana, India
INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS
TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED
Opinion and Conclusion
We have (a) audited the Consolidated Financial Results for the year ended March 31, 2026 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2026 (refer ‘Other Matters’ section below), which were subject to limited review by us, both included in the accompanying “Statement of audited consolidated financial results for the year ended March 31, 2026 and unaudited consolidated financial results for the quarter ended March 31, 2026” of AUROBINDO PHARMA LIMITED (the “Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as the “Group”), and its share of the net profit after tax and other comprehensive income of its joint ventures and associates for the quarter and year ended March 31, 2026, (the “Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “LODR Regulations”).
(a) Opinion on Annual Consolidated Financial Results
In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on separate financial statements of subsidiaries, associates and joint ventures referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2026:
(i) includes the financial results of the subsidiaries, associates and joint ventures listed in Annexure I.
(ii) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
(iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group for the year ended March 31, 2026.
(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2026
With respect to the Unaudited Consolidated Financial Results for the quarter ended March 31, 2026, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor’s Responsibilities section below and based on the consideration of the review reports of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2026, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2026
We conducted our audit in accordance with the Standards on Auditing (“SA”s) specified under Section 143(10) of the Companies Act, 2013 (the “Act”). Our responsibilities under those Standards are further described in paragraph (a) of Auditor’s Responsibilities section below. We are independent of the Group, its associates and joint ventures in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the “ICAI”) together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI’s Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.
1
Deloitte Haskins & Sells
Management's and Board of Directors' Responsibilities for the Statement
This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2026, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2026 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group including its associates and joint ventures in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations.
The respective Board of Directors of the companies included in the Group and of its associates and joint ventures are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and its associates and joint ventures and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.
In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group and of its associates and joint ventures are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.
The respective Board of Directors of the companies included in the Group and of its associates and joint ventures are responsible for overseeing the financial reporting process of the Group and of its associates and joint ventures.
Auditor's Responsibilities
(a) Audit of the Consolidated Financial Results for the year ended March 31, 2026
Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.
As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
-
Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
-
Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
-
Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
-
Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
Deloitte Haskins & Sells
-
Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and its associates and joint ventures to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and joint ventures to cease to continue as a going concern.
-
Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
-
Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations to the extent applicable.
-
Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the entities within the Group and its associates and joint ventures to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.
Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.
We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.
We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2026
We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2026 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under Section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.
We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
L
Deloitte Haskins & Sells
Other Matters
-
The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.
-
We did not audit the financial statements of 73 subsidiaries included in the consolidated financial results, whose financial statements reflect total assets of ₹ 455,816.3 million as at March 31, 2026 and total revenues of ₹ 72,701.5 million and ₹ 267,501.9 million for the quarter and year ended March 31, 2026 respectively, total net profit after tax of ₹ 5,013.7 million and ₹ 10,256.9 million for the quarter and year ended March 31, 2026 respectively and total comprehensive income of ₹ 5,018.0 million and ₹ 10,249.2 million for the quarter and year ended March 31, 2026 respectively and net cash flows of ₹ 3,019.3 million for the year ended March 31, 2026, as considered in the Statement. The consolidated financial results also includes the Group's share of total net loss after tax of ₹ 20.2 million and ₹ 3.6 million for the quarter and year ended March 31, 2026 respectively and total comprehensive loss of ₹ 20.0 million and ₹ 3.4 million for the quarter and year ended March 31, 2026 respectively, as considered in the Statement, in respect of 3 joint ventures whose financial statements have not been audited by us. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and joint ventures, is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above.
-
The consolidated financial results includes the unaudited financial statements of 4 subsidiaries, whose financial statements reflect total assets of Rs. nil million as at March 31, 2026 and total revenues of Rs nil million for the quarter and year ended March 31, 2026 respectively, total net profit / (loss) after tax of Rs nil million for the quarter and year ended March 31, 2026 respectively and other comprehensive income / loss of Rs nil million for the quarter and year ended March 31, 2026 respectively and net cash flows of Rs. nil million for the year ended March 31, 2026 as considered in the Statement. The consolidated financial results also includes the Group's share of profit/(loss) after tax of ₹ (4.3) million and ₹ 18.6 million for the quarter and year ended March 31, 2026 respectively and total comprehensive income / (loss) of ₹ (4.3) million and ₹ 18.6 million for the quarter and year ended March 31, 2026 respectively, as considered in the Statement, in respect of 2 associates whose financial statements have not been audited by us. These financial statements are unaudited and have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associates, is based solely on such unaudited financial statements. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial statements are not material to the Group.
Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.
For DELOITTE HASKINS & SELLS
Chartered Accountants
(Firm's Registration No. 0080725)
C Manish Muralidhar
Partner
(Membership No. 213649)
(UDIN: 26213649NPFYGR6309)
Place: Nellore
Date: May 21, 2026
Deloitte Haskins & Sells
Annexure I to the Independent Auditor's Report on Audit of Annual Consolidated Financial Results and review of Quarterly Financial results
The consolidated financial results include results of the following entities:
| S.No | Name of Component | Country | Relationship |
|---|---|---|---|
| 1 | Helix Healthcare B.V. | The Netherlands | Direct Subsidiary |
| 2 | APL Pharma Thai Limited | Thailand | Direct Subsidiary |
| 3 | Aurobindo Pharma Industria Farmaceutica Ltd | Brazil | Direct Subsidiary |
| 4 | Aurobindo Pharma Produtos Farmaceuticos Limitada | Brazil | Direct Subsidiary |
| 5 | All Pharma (Shanghai) Trading Co Ltd | China | Direct Subsidiary |
| 6 | Aurobindo Pharma USA Inc. | USA | Direct Subsidiary |
| 7 | APL Healthcare Limited | India | Direct Subsidiary |
| 8 | Auro Peptides Limited | India | Direct Subsidiary |
| 9 | Apitoria Pharma Private Limited | India | Direct Subsidiary |
| 10 | Auroactive Pharma Private Limited | India | Direct Subsidiary |
| 11 | CuraTeQ Biologics Private Limited | India | Direct Subsidiary |
| 12 | AuroZest Private Limited | India | Direct Subsidiary |
| 13 | Aurobindo Antibiotics Private Limited | India | Direct Subsidiary |
| 14 | Eugia Pharma Specialities Limited | India | Direct Subsidiary |
| 15 | GLS Pharma Limited | India | Direct Subsidiary |
| 16 | TheraNyM Biologics Private Limited | India | Direct Subsidiary |
| 17 | Auropharm Limited | ||
| (formerly known as Auro Pharma Limited) | India | Direct Subsidiary | |
| 18 | Aurobindo Pharma Foundation | India | Direct Subsidiary |
| 19 | Auro Vaccines Private Limited | India | Step-Down Subsidiary |
| 20 | Agile Pharma B.V. | The Netherlands | Step-Down Subsidiary |
| 21 | Milpharm Limited | United Kingdom | Step-Down Subsidiary |
| 22 | Aurobindo Pharma (Malta) Ltd | Malta | Step-Down Subsidiary |
| 23 | APL Swift Services (Malta) Ltd | Malta | Step-Down Subsidiary |
| 24 | Aurobindo Pharma (Romania) s.r.l | Romania | Step-Down Subsidiary |
| 25 | Pharmacin B.V. | ||
| (Merged with Agile Pharma B.V. w.e.f July 01, 2025) | The Netherlands | Step-Down Subsidiary | |
| 26 | Aurovitas Pharma Polska | Poland | Step-Down Subsidiary |
| 27 | Generis Farmaceutica S.A. | Portugal | Step-Down Subsidiary |
| 28 | Generis Phar, Unipessoal Lda | Portugal | Step-Down Subsidiary |
| 29 | Aurobindo Pharma (Italia) S.r.l | Italy | Step-Down Subsidiary |
| 30 | Arrow Generiques SAS | France | Step-Down Subsidiary |
| 31 | 1980 Puren Pharma GmbH, Germany | Germany | Step-Down Subsidiary |
| 32 | Puren Pharma GmbH & Co., KG | Germany | Step-Down Subsidiary |
| 33 | Aurovitas Spain SA | Spain | Step-Down Subsidiary |
| 34 | Aurobindo Pharma B.V. | The Netherlands | Step-Down Subsidiary |
| 35 | Aurovitas Spol s.r.o | Czech Republic | Step-Down Subsidiary |
| 36 | Apotex Europe B.V. | The Netherlands | Step-Down Subsidiary |
| 37 | Aurovitas Nederland B.V | The Netherlands | Step-Down Subsidiary |
| 38 | Sameko Farma B.V. | The Netherlands | Step-Down Subsidiary |
| 39 | Leidapharm B.V. | The Netherlands | Step-Down Subsidiary |
| 40 | Marel B.V. | The Netherlands | Step-Down Subsidiary |
| 41 | Pharma Dossier B.V. | The Netherlands | Step-Down Subsidiary |
| 42 | Aurobindo NV/SA | Belgium | Step-Down Subsidiary |
| 43 | CuraTeQ Biologics s.r.o. | Czech Republic | Step-Down Subsidiary |
| 44 | Eugia Pharma B.V. | The Netherlands | Step-Down Subsidiary |
| 45 | Eugia Pharma (Malta) Limited | Malta | Step-Down Subsidiary |
| 46 | Eugia (UK) Limited | United Kingdom | Step-Down Subsidiary |
| 47 | Auro Pharma Inc. | Canada | Step-Down Subsidiary |
| 48 | Aurobindo Pharma (Pty) Ltd | South Africa | Step-Down Subsidiary |
| 49 | Aurobindo Pharma Japan KK | Japan | Step-Down Subsidiary |
| 50 | Aurovida Farmaceutica SA DE CV | Mexico | Step-Down Subsidiary |
| 51 | Aurobindo Pharma Colombia S.A.S | Colombia | Step-Down Subsidiary |
| 52 | Aurogen South Africa (PTY) Ltd | South Africa | Step-Down Subsidiary |
1
Deloitte Haskins & Sells
| S.No | Name of Component | Country | Relationship |
|---|---|---|---|
| 53 | Aurobindo Pharma Saudi Arabia Ltd Company | Saudi Arabia | Step-Down Subsidiary |
| 54 | Aurovitas Pharma (Taizhou) Ltd | China | Step-Down Subsidiary |
| 55 | Aurobindo Pharma FZ-LLC | Dubai | Step-Down Subsidiary |
| 56 | Aurosalud SA De CV | Mexico | Step-Down Subsidiary |
| 57 | Auro PR Inc. | Puerto Rico | Step-Down Subsidiary |
| 58 | Eugia Pharma Inc. | Canada | Step-Down Subsidiary |
| 59 | Eugia Pharma (Australia) PTY Limited | Australia | Step-Down Subsidiary |
| 60 | Eugia Pharma Industria Farmaceutica Limitada | Brazil | Step-Down Subsidiary |
| 61 | Aurobindo Pharma Ukraine LLC | Ukraine | Step-Down Subsidiary |
| 62 | Eugia Pharma Colombia S.A.S. | Colombia | Step-Down Subsidiary |
| 63 | PT Aurogen Pharma | Indonesia | Step-Down Subsidiary |
| 64 | Aurolife Pharma LLC | USA | Step-Down Subsidiary |
| 65 | Auro Health LLC | USA | Step-Down Subsidiary |
| 66 | Auro AR LLC | USA | Step-Down Subsidiary |
| 67 | Auro Vaccines LLC | USA | Step-Down Subsidiary |
| 68 | AuroLogistics LLC | USA | Step-Down Subsidiary |
| 69 | Acrotech Biopharma Inc | USA | Step-Down Subsidiary |
| 70 | Auro Science LLC | USA | Step-Down Subsidiary |
| 71 | Auro Packaging LLC | USA | Step-Down Subsidiary |
| 72 | Vespyr Brands, LLC | USA | Step-Down Subsidiary |
| 73 | Eugia Inc. | USA | Step-Down Subsidiary |
| 74 | Eugia US LLC | USA | Step-Down Subsidiary |
| 75 | Eugia US Manufacturing LLC | USA | Step-Down Subsidiary |
| 76 | Eugia Steriles Private Limited | India | Step-Down Subsidiary |
| 77 | Lyflux Pharma Private Limited | India | Step-Down Subsidiary |
| 78 | Qule Pharma Private Limited | India | Step-Down Subsidiary |
| 79 | Eugia SEZ Private Limited | India | Step-Down Subsidiary |
| 80 | Auro Pharma LLC | Russia | Step-Down Subsidiary |
| 81 | Purple Bellflower, South Africa | South Africa | Step-Down Subsidiary |
| 82 | Ace Laboratories Limited | United Kingdom | Step-Down Subsidiary |
| 83 | Cresedemo Pharma LLC | ||
| (w.e.f. June 13, 2025) | USA | Step-Down Subsidiary | |
| 84 | Curateq Biologics B.V | ||
| (w.e.f May 28, 2025) | The Netherlands | Step-Down Subsidiary | |
| 85 | Aurobindo Pharma (Malaysia) SDN. BHD. | ||
| (w.e.f September 17, 2025) | Malaysia | Step-Down Subsidiary | |
| 86 | CuraTeQ Biologics (Malta) Limited | ||
| (w.e.f September 26, 2025) | Malta | Step-Down Subsidiary | |
| 87 | Aurobindo Pharma Chile SpA | ||
| (w.e.f October 07, 2025) | Chile | Step-Down Subsidiary | |
| 88 | Eugia Pharma Chile SpA | ||
| (w.e.f October 07, 2025) | Chile | Step-Down Subsidiary | |
| 89 | Aurobindo Pharma Philippines Inc | ||
| (w.e.f January 23, 2026) | Philippines | Step-Down Subsidiary | |
| 90 | Diadame Pharma SARL | ||
| (w.e.f January 1, 2026) | Senegal | Step-Down Subsidiary | |
| 91 | Engenra Biologics Private Limited | ||
| (w.e.f February 24, 2026) | India | Direct Subsidiary | |
| 92 | Luoxin Aurovitas Pharm (Chengdu) Co. Ltd. | China | Joint venture |
| 93 | Raidurgam Developers Limited | Indias | Joint venture |
| 94 | Tergene Biotech Limited | India | Joint venture |
| 95 | NVNR (Ramannapet I) Power Plant Private Limited | India | Associate |
| 96 | NVNR (Ramannapet II) Power Plant Private Limited | India | Associate |
L
AUROBINDO
Annexure - 1
Details as required pursuant to Regulation 30 of SEBI Listing Regulations
| Sl No. | Particulars | Details |
|---|---|---|
| 1 | Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise; | Resignation of M/s. MRR & Associates, Secretarial Auditors of the Company due to health issues of its sole proprietor |
| 2 | Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment; | With effect from May 22, 2026 |
| 3 | Brief Profile (in case of appointment) | Not applicable |
| 4 | Disclosure of relationships between directors (in case of appointment of a director) | Not applicable |
Digitally signed by ADI REDDY BADDIGAM
Date: 2026.05.21 19:27:24 +05'30'
(CIN : L24239TG1986PLC015190)
A U R O B I N D O P H A R M A L I M I T E D
www.aurobindo.com
Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.
Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: [email protected] Website: www.aurobindo.com
AUROBINDO
Annexure - 2
Details as required pursuant to Regulation 30 of SEBI Listing Regulations
| Sl No. | Particulars | Details |
|---|---|---|
| 1 | Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise; | Appointment of M/s. RPR & Associates, Company Secretaries, Peer Reviewed Firm of Company Secretaries in Practice (Firm registration number: S2017TL469100), as Secretarial Auditors of the Company. |
| 2 | Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment; | May 21, 2026 |
| For a term of five consecutive years commencing from FY 2026-27 to FY 2030-31, subject to approval of the shareholders at the ensuing Annual General Meeting. | ||
| 3 | Brief Profile (in case of appointment) | M/s. RPR & Associates is a firm of company secretaries in practice. They have experience in delivering comprehensive professional services across Corporate Laws, SEBI Regulations and FEMA Regulations. Their expertise includes conducting Secretarial Audits, Due Diligence Audits, Compliance Audits etc. |
Mr. Y. Ravi Prasada Reddy, Proprietor of M/s. RPR & Associates, has been practicing as a Company Secretary for over 23 years. The firm possesses rich experience in corporate laws and is supported by a skilled and dedicated team. |
| 4 | Disclosure of relationships between directors (in case of appointment of a director) | Not applicable |
Digitally signed by ADI REDDY
BADDIGAM
Date: 2026.05.21 19:27:52 +05'30'
(CIN: L24239TG1986PLC015190)
AUROBINDO PHARMA LIMITED
www.aurobindo.com
Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.
Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: [email protected] Website: www.aurobindo.com
AUROBINDO
Annexure - 3
Details as required pursuant to Regulation 30 of SEBI Listing Regulations
| Sl No. | Particulars | Details |
|---|---|---|
| 1 | Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise; | Re-appointment of M/s. Ernst & Young LLP (EY) as Internal Auditors of the Company |
| 2 | Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment; | May 21, 2026 (for the period from June 2026 to May 2027) |
| 3 | Brief Profile (in case of appointment) | EY is a global leader in assurance, tax, transaction, and advisory services, recognized for its commitment to enhancing risk management, control, and governance processes through its Internal Audit (IA) services. By leveraging extensive industry knowledge and innovative methodologies, EY delivers tailored solutions that address unique organizational challenges. Their focus areas include risk assessment, process improvement, technology integration, regulatory compliance, and stakeholder engagement. Overall, EY's IA services provide valuable assurance and insights that support informed decision-making and contribute to the long-term success of organizations. |
| 4 | Disclosure of relationships between directors (in case of appointment of a director) | Not applicable |
Digitally signed by ADI REDDY BADDIGAM
Date: 2026.05.21 19:28:25 +05'30'
(CIN : L24239TG1986PLC015190)
A U R O B I N D O P H A R M A L I M I T E D
www.aurobindo.com
Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.
Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: [email protected] Website: www.aurobindo.com